BEN arrives at its April 30 Q2 results with one notable tension: the stock has just had its best month in years, yet almost every analyst covering it still rates it a sell.
Options traders have turned noticeably more bullish into the print. The put/call ratio fell to 0.45 — well below its 20-day average of 0.49 — and sits near the low end of its 52-week range of 0.30–1.04. That's a tilt toward calls rather than downside protection, consistent with the sharp price recovery: BEN closed at $29.46, up 29% over the past month and 8% on the week alone. A 14-day RSI of 65 signals momentum without yet reaching overbought territory.
The Street, however, is not buying the rally. Both Barclays and Evercore ISI carry outright underperform ratings, and a Morgan Stanley Underweight is still on the books with a $22 target — well below where the stock is trading today. Barclays nudged its target to $26 on April 17, and Evercore trimmed to $27 on April 10. Only TD Cowen holds a Buy, with a $30 target. The consensus mean price target is $27.41, implying the average analyst sees the stock as already overvalued at current levels. The dividend yield of 4.8% and a dividend score in the 98th percentile offer income-focused investors a concrete counterargument, but the EV/EBITDA of 6.9x and a trailing P/E north of 57x leave little room for disappointment on earnings quality.
Short interest is a secondary story here. Bears hold 4.6% of the free float — modest enough that there is no squeeze dynamic at play. Borrow availability is loose, with cost to borrow at just 0.50% and lending conditions relaxed. Short positions have actually eased roughly 3% over the past week, suggesting that at least some bears covered into the run-up rather than pressing the bet. The ORTEX short score of 49.3 is mid-range and has drifted lower from above 51 two weeks ago — confirming that short-side conviction has softened alongside the price recovery.
Ownership adds an interesting layer. The Johnson family — founders of the firm — collectively hold well above 40% of shares outstanding across Rupert, Charles, and other family members. Charles Bartlett Johnson purchased $2.1 million worth of shares in November at around $21, a buy that now looks well-timed with the stock 40% higher. The family's concentrated control means the print is as much about their confidence in management direction as it is about quarterly numbers.
The April 30 report will test whether the revenue and margin profile — last quarter's net income margin came in at 11% on $2.3 billion in revenue — can justify a valuation that the majority of covering analysts already regard as stretched.
See the live data behind this article on ORTEX.
Open BEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
